INCENTIVE STOCK OPTION AGREEMENT UNDER THE AEGERION PHARMACEUTICALS, INC.Incentive Stock Option Agreement • March 3rd, 2014 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations
Aegerion Pharmaceuticals, Inc. (the “Company”) hereby grants to the Optionee named above an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value $0.001 per share (the “Stock”), of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions of the Company’s 2010 Stock Option and Incentive Plan (as amended from time to time, the “Plan”) and the Company’s Long Term Incentive Program (the “LTIP”). Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.
SECOND LOAN MODIFICATION AGREEMENTLoan Modification Agreement • March 3rd, 2014 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations
This Second Loan Modification Agreement (this “Loan Modification Agreement”) is entered into as of December 6, 2012, by and between SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production office located at 275 Grove Street, Suite 2-200, Newton, Massachusetts 02466 (“Bank”) and AEGERION PHARMACEUTICALS, INC., a Delaware corporation with its chief executive office located at 101 Main Street, Suite 1850, Cambridge, Massachusetts 02142(“Borrower”).
FOURTH AMENDMENT TO LEASELease • March 3rd, 2014 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS FOURTH AMENDMENT TO LEASE, dated as of January 1, 2014 (this “Amendment”), between RREEF AMERICA REIT II CORP. PPP, a Maryland corporation (“Landlord”), and AEGERION PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”), for certain premises located in the building in Riverfront Office Park at 101 Main Street, Cambridge, Massachusetts (referred to in the Lease as the “Building” and in this Amendment as the “101 Main Building”).
CONSENT AND THIRD LOAN MODIFICATION AGREEMENTLoan Modification Agreement • March 3rd, 2014 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations
This Consent and Third Loan Modification Agreement (this “Loan Modification Agreement”) is entered into as of December 12, 2013, by and between SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production office located at 275 Grove Street, Suite 2-200, Newton, Massachusetts 02466 (“Bank”) and AEGERION PHARMACEUTICALS, INC., a Delaware corporation with its chief executive office located at 101 Main Street, Suite 1850, Cambridge, Massachusetts 02142 (“Borrower”).
